LUMINARI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.377
EU - Europa 9.011
AS - Asia 2.847
SA - Sud America 102
OC - Oceania 51
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 8
Totale 31.431
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.262
GB - Regno Unito 3.533
DE - Germania 1.529
IT - Italia 1.421
CN - Cina 975
SE - Svezia 968
HK - Hong Kong 593
UA - Ucraina 453
TR - Turchia 407
SG - Singapore 370
FI - Finlandia 279
FR - Francia 239
BG - Bulgaria 222
RU - Federazione Russa 83
VN - Vietnam 79
ID - Indonesia 78
JP - Giappone 76
CA - Canada 67
IN - India 65
IE - Irlanda 64
KR - Corea 62
AU - Australia 47
BR - Brasile 42
CH - Svizzera 39
ES - Italia 27
MY - Malesia 24
BZ - Belize 23
IR - Iran 23
BE - Belgio 20
RO - Romania 20
LT - Lituania 18
MX - Messico 18
NL - Olanda 16
TH - Thailandia 16
AR - Argentina 15
CZ - Repubblica Ceca 15
EG - Egitto 14
IL - Israele 14
CL - Cile 12
PL - Polonia 12
TW - Taiwan 12
PE - Perù 10
PK - Pakistan 10
CO - Colombia 9
NO - Norvegia 7
EC - Ecuador 6
JO - Giordania 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
GR - Grecia 5
HU - Ungheria 5
PH - Filippine 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
DK - Danimarca 4
DZ - Algeria 4
EU - Europa 4
LU - Lussemburgo 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RS - Serbia 4
BD - Bangladesh 3
BO - Bolivia 3
HR - Croazia 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BH - Bahrain 2
CR - Costa Rica 2
GP - Guadalupe 2
IQ - Iraq 2
KE - Kenya 2
LV - Lettonia 2
MW - Malawi 2
NP - Nepal 2
PA - Panama 2
PY - Paraguay 2
SI - Slovenia 2
UZ - Uzbekistan 2
VE - Venezuela 2
A1 - Anonimo 1
AL - Albania 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
IS - Islanda 1
KH - Cambogia 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
QA - Qatar 1
SN - Senegal 1
Totale 31.431
Salva come PNG Salva come JPEG
Città #
Fairfield 3.243
Southend 3.027
Woodbridge 1.849
Ashburn 1.675
Houston 1.416
Chandler 1.210
Seattle 1.173
Wilmington 1.083
Cambridge 1.061
Frankfurt am Main 972
Jacksonville 922
Dearborn 813
Ann Arbor 785
Nyköping 605
Hong Kong 583
Beijing 400
San Diego 307
Singapore 258
Modena 248
Princeton 238
Sofia 221
Izmir 205
Redwood City 193
Eugene 186
New York 143
Helsinki 120
London 116
Milan 104
Shanghai 89
Bremen 72
Jakarta 64
Dong Ket 62
Rome 62
Falls Church 59
Dublin 53
Des Moines 50
Boardman 46
Tappahannock 42
Norwalk 39
San Jose 39
Bologna 38
Kilburn 38
Philadelphia 30
Phoenix 30
Hefei 27
Istanbul 27
Chicago 25
Los Angeles 24
Parma 24
Belize City 23
Chiswick 23
Kunming 23
Nanjing 23
Munich 21
Reggio Nell'emilia 21
Saint Petersburg 21
San Mateo 21
Brussels 20
Hounslow 20
Palermo 20
Paris 20
San Francisco 20
Toronto 19
Guangzhou 18
Tokyo 18
Fremont 17
Albuquerque 15
Changsha 15
Dallas 15
Naples 14
Saint Louis 14
Augusta 13
Hanoi 13
Ottawa 13
Prescot 13
Turin 13
Jinan 12
Las Vegas 12
San Giuliano Milanese 12
Segrate 12
Seongnam 12
Verona 12
Bari 11
Hangzhou 11
Kuala Lumpur 11
Lima 11
Manchester 11
Brno 10
Florence 10
Imola 10
Nanchang 10
Rio Saliceto 10
Seoul 10
Columbus 9
Hebei 9
Incheon 9
Sydney 9
São Paulo 9
Berlin 8
Catania 8
Totale 24.830
Salva come PNG Salva come JPEG
Nome #
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study 680
Survival of cancer patients in Italy [La sopravvivenza dei pazienti oncologici in Italia [La sopravvivenza dei pazienti oncologici in Italia] 678
Veno-occlusive disease nurse management: Development of a dynamic monitoring tool by the GITMO nursing group 594
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 513
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 508
T-cell lymphoma in South America and Europe. 375
Il linfoma mantellare 288
Transformed follicular lymphoma 283
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 245
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 233
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 227
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 213
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. 212
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 211
A Gene Expression–based Model to Predict Metabolic Response after Two Courses of ABVD in Hodgkin Lymphoma Patients 211
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 209
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 208
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 207
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 207
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 206
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 203
Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma. 202
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 200
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 200
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 195
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 194
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 193
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 192
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 191
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 190
Reply to T.P. Vassilakopoulos et al 190
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma 189
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 189
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 188
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 188
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 187
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 187
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 187
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 185
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials 184
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 181
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 180
Reply to H.J.A. Adams et al and E. Laffon et al 180
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients 178
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 178
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 177
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 177
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: A subset analysis of NCIC CTG LY12 175
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 175
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) 175
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 173
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 172
Bendamustine salvage therapy for T cell neoplasms 172
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 172
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 172
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 170
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 170
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 170
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi Study 170
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system 169
Novel prognostic tools that identify high-risk follicular lymphoma 169
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) 167
Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. 167
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy 167
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. 167
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 167
Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. 166
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 165
The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study 164
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 164
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 164
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. 163
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 163
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale 163
Prognostic assessment in patients with indolent B-cell lymphomas 162
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 162
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi 162
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 162
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 161
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 160
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 160
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 158
Prognostic tools in follicular lymphomas 157
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 156
Prognosis of follicular lymphomas 155
The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma) 155
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma 154
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 154
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project 154
Case studies of elderly patients with non-Hodgkin's lymphoma. 153
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 152
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 152
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 151
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 151
Cancer incidence in people with AIDS in Italy 151
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 151
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 149
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 148
Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy. 148
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 147
Totale 20.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.545
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.545
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.177 0 0 252 556 697 1.064 1.112 709 797 334 390 266
2020/20216.267 506 286 588 608 679 468 436 675 472 664 495 390
2021/20224.667 325 538 521 270 134 271 245 297 471 365 804 426
2022/20233.849 419 393 324 330 460 504 96 396 465 97 220 145
2023/20244.005 113 207 185 229 1.442 205 411 669 78 79 89 298
2024/2025434 313 88 33 0 0 0 0 0 0 0 0 0
Totale 32.045